Telo Genomics Presents Genomic Profiles of Peripheral Blood Minimal Residual Disease Cells at the 67th American Society of Hematology Meeting

Rhea-AI Summary

Telo Genomics (OTCQB: TDSGF) presented initial clinical results for a peripheral blood MRD test in multiple myeloma at the 67th ASH meeting on December 11, 2025.

The poster describes a combined approach that enumerates individual circulating tumor cells and applies TeloView 3D telomere profiling, reporting a limit of detection of 1 in 107 cells and identification of distinct 3D genome clusters that correlate with high/low mutation patterns. The abstract was published in Blood and the poster is available on the company website. Larger validation studies are underway to assess predictive power for relapse risk.

News Market Reaction

+12.94%

1 alert

+12.94% News Effect

On the day this news was published, TDSGF gained 12.94%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Limit of detection: 1 in 10^7 cells Blood cell comparator: 10 million blood cells ASH meeting edition: 67th meeting

3 metrics

Limit of detection 1 in 10^7 cells MRD testing sensitivity for MM CTCs in peripheral blood

Blood cell comparator 10 million blood cells One myeloma cell detected among 10 million blood cells

ASH meeting edition 67th meeting American Society of Hematology Annual Meeting in Orlando

Market Reality Check

Price: $0.0365 Vol: Volume 9,260 is slightly ...

normal vol

$0.0365 Last Close

Volume Volume 9,260 is slightly below the 20-day average of 10,060 (relative volume 0.92). normal

Technical Shares at $0.034 are trading below the 200-day MA of $0.09 and remain far under the $0.1793 52-week high.

Peers on Argus

Peer performance is mixed: FUNI up 12.78%, IDXG down 7.24%, ICBU down 11.76%, wh...

Peer performance is mixed: FUNI up 12.78%, IDXG down 7.24%, ICBU down 11.76%, while SZLSF and RNVA are flat. This points to a stock-specific reaction rather than a broad diagnostics move.

Historical Context

5 past events · Latest: Oct 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Oct 09	ASH abstract news	Positive	-21.4%	ASH acceptance of MRD abstract for TeloView-based myeloma liquid biopsy.
Sep 30	Facility expansion	Positive	+12.1%	Relocation to larger Toronto lab to handle rising diagnostic test demand.
Sep 08	IR engagement	Positive	-4.7%	Engagement of Hayden IR under a 12‑month, fee-based IR agreement.
Aug 05	Investor conference	Positive	+5.9%	OTCQB virtual conference presentation on myeloma assay commercialization strategy.
Jun 30	Executive lawsuit	Negative	+16.1%	Former president’s claim for about <b>$530,000</b> in alleged unpaid compensation.

Pattern Detected

Reactions to news have been mixed: operational and conference updates sometimes aligned positively, while prior positive ASH-related and legal headlines saw divergent moves.

Recent Company History

Over the last six months, Telo Genomics reported several milestones, including a new Toronto lab facility to meet growing test demand, an investor relations engagement, and participation in an OTCQB investor conference. It also disclosed a lawsuit from a former president seeking about $530,000. An earlier ASH abstract acceptance on Oct 09 preceded a notable selloff. Today’s detailed ASH poster on MM MRD builds directly on that abstract, providing initial clinical results and deeper validation of the TeloView platform.

Market Pulse Summary

The stock surged +12.9% in the session following this news. A strong positive reaction aligns with t...

Analysis

The stock surged +12.9% in the session following this news. A strong positive reaction aligns with the clinically focused nature of this ASH poster, which detailed MRD detection down to 1 in 10^7 cells and distinct 3D genome profiles in MM CTCs. Historically, Telo’s news flow showed both aligned moves (lab expansion, investor conference) and sharp divergences, including a selloff after ASH abstract acceptance. Investors evaluating sustainability could compare this move to those past reactions and factor in legal overhangs disclosed on Jun 30.

Key Terms

minimal residual disease, circulating tumor cells, liquid biopsies

3 terms

minimal residual disease medical

"approach to Multiple Myeloma (MM) Minimal Residual Disease (MRD) testing with a poster"

Minimal residual disease (MRD) is the tiny number of cancer cells that remain in the body after treatment, often too few to show up on standard scans but detectable with very sensitive tests. For investors, MRD is important because it predicts the risk of relapse and can determine whether a therapy is seen as effective, influences regulatory and reimbursement decisions, and affects the size and timing of a drug’s market opportunity—like spotting the last weeds that can make a garden regrow if not removed.

circulating tumor cells medical

"combines the enumeration of individual MM Circulating Tumor Cells (CTCs) from peripheral blood"

Circulating tumor cells are cancer cells that break away from a tumor and travel in the bloodstream, detectable through a blood test. Investors care because their presence and number can act like a real-time signal — similar to footprints showing where a person has been — revealing disease progression, response to treatment, or risk of metastasis, which influences the market value of diagnostics, therapies and clinical trial outcomes.

liquid biopsies medical

"minimal residual disease testing in myeloma: liquid biopsies to enumerate and 3D telomere-profile"

Liquid biopsies are non‑surgical tests that look for tiny pieces of tumor material, such as DNA or cells, circulating in body fluids (usually blood) to detect or monitor cancer. For investors, they matter because they offer faster, cheaper and less invasive ways to catch disease earlier and track treatment response, which can shift how diagnostics, drug trials and ongoing care are paid for and create sizable commercial opportunities — like a smoke detector sensing a fire without opening the walls.

AI-generated analysis. Not financial advice.

Toronto, Ontario--(Newsfile Corp. - December 11, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that the company highlighted its approach to Multiple Myeloma (MM) Minimal Residual Disease (MRD) testing with a poster presentation during the 67^th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.

The poster presentation describes the initial clinical results of a new MRD evaluation that combines the enumeration of individual MM Circulating Tumor Cells (CTCs) from peripheral blood with the TeloView® 3D telomere profiling platform. Telo demonstrated that this approach consistently performs at a 1 in 10^7 limit of detection (finding one myeloma cell among 10 million blood cells) at different stages of the disease.

Furthermore, TeloView® has identified distinct clusters of 3D genome profiles that characterize groups of individual patients and correlate to known patterns of high/low mutation rates. Larger studies are underway to validate the predictive power of these MRD profiles in determining risk of relapses, similar to the prognostic TeloView models for newly diagnosed MM and smoldering multiple myeloma.

The abstract titled "Novel method of minimal residual disease testing in myeloma: liquid biopsies to enumerate and 3D telomere-profile circulating tumor cells", was presented by Dr. Yulia Shifrin, Laboratory Director of Telo Genomics. The abstract has also been published in the conference journal Blood, and the presentation poster is available on the Company website.

"This method provides functional, biological information about the residual disease cells themselves, offering insights into progression risk beyond cell counts," said Dr. Sabine Mai, co-founder and interim CEO of Telo Genomics. "At the same time, evaluating CTCs from peripheral blood reduces reliance on repeated bone marrow procedures and makes continuous monitoring far more feasible."

About MRD Assessment

Minimal Residual Disease ("MRD") is defined as the small number of cancer cells that remain in the body after treatment, stratifying MRD cells, between being in remission or active, provides important actionable information for clinicians. Also, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted unanimously in April 2024 to accept MRD as a clinical endpoint for accelerated approval of new multiple myeloma therapies, paving the way for faster drug approvals in multiple myeloma.

MRD testing is emerging as a valuable tool in assessing treatment response and guiding therapeutic decisions in oncology. With advancements in drug development technologies, and a growing emphasis on personalized healthcare, the MRD testing industry is expected to exhibit substantial global expansion in the coming years. The MRD global testing market size is expected to reach USD 4.1 billion by 2032.

About Multiple Myeloma

Multiple myeloma is a challenging and potentially deadly blood cancer that involves plasma cells, a type of blood cell that helps to fight infection. It is the second most common blood cancer with an incidence of 35,000 new cases every year in the US, and ~180,000 patients receiving treatment at any given time. The introduction of next-generation therapies (including targeted treatments) has increased the median survival rate to over 5 years, but MM is still considered incurable. Two asymptomatic precursors, Monoclonal Gammopathy of Unknown Significance ("MGUS") and SMM generally precede the progression to classic symptomatic MM. While MGUS carries a steady risk of progression of 1% per year, SMM is more heterogenous with nearly 40% of patients progressing in the first 5 years, 15% in the next 5 years, reaching the same low risk as MGUS after 10 years. To date, identifying patients who will more rapidly progress to MM remains an important clinical need. MM treatment includes various combinations of drugs with a cost as high as $150,000 per year per patient. As most patients will develop resistance to treatment and relapse within a median of 2 years, identifying them proactively remains another important clinical need. Notably, the total addressable market for both MM assays is over 750,000 tests per year in the US.

About Telo Genomics

Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information, please visit www.telodx.com.

For further information, please contact:
Guido Baechler
Executive Chairman
647-477-9365
info@telodx.com
555 Richmond Street West,
Toronto, ON, Canada, M5V 3B1
www.telodx.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Certain forward-looking statements, including statements regarding the Company's receipt of TSXV acceptance of the stock option grant are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277698

FAQ

What did Telo Genomics (TDSGF) present at the 67th ASH meeting on December 11, 2025?

Telo Genomics presented a poster on a peripheral blood MRD test combining CTC enumeration with TeloView 3D telomere profiling and published the abstract in Blood.

What limit of detection did Telo Genomics report for its MRD test (TDSGF)?

The company reported a limit of detection of 1 in 10⁷, meaning one myeloma cell detected among ten million blood cells.

How does TeloView profiling affect MRD assessment in multiple myeloma (TDSGF)?

TeloView identified distinct 3D genome clusters among patients that correlate with known high/low mutation patterns, offering biological context beyond cell counts.

Who presented the Telo Genomics MRD abstract at ASH 2025 and where is the poster available?

Dr. Yulia Shifrin presented the abstract; the poster is available on the company's website and the abstract is published in Blood.

Will Telo Genomics (TDSGF) run further studies to validate the MRD profiles?

Yes, the company stated that larger validation studies are underway to assess predictive power for relapse risk.

Does the Telo Genomics MRD method reduce the need for bone marrow biopsies (TDSGF)?

The company says evaluating circulating tumor cells from peripheral blood reduces reliance on repeated bone marrow procedures and may enable easier continuous monitoring.